Clinical and virologic outcomes over duration on ART, ARV-naïve patients.

<p>A) median CD4+ cell count (cells/mm³) over time on ART; and, B) percentage of patients with virologic suppression (≤400 copies/mL) over time on ART.</p

Median follow-up time on ART by first-line ART regimen, ARV-naïve patients (N = 70,002).

<p>Median follow-up time on ART by first-line ART regimen, ARV-naïve patients (N = 70,002).</p

First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).

<p>First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).</p

Characterization of treatment failure over time.

<p>A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of patients with virologic failure within first 18 months on ART by enrollment year.</p

Median age at ART initiation by sex, ARV-naïve patients (N = 70,002).

<p>Median age at ART initiation by sex, ARV-naïve patients (N = 70,002).</p

Immunologic, virologic and adherence patterns by baseline CD4+ cell count, previously ARV-naïve patients (N = 70,002).

<p>Immunologic, virologic and adherence patterns by baseline CD4+ cell count, previously ARV-naïve patients (N = 70,002).</p

Predictors of virologic and immunologic failure for ARV-naïve patients.

<p>Predictors of virologic and immunologic failure for ARV-naïve patients.</p

Baseline patient status by enrollment year, ARV-naïve patients.

<p>A) median baseline CD4+cell count (cell/mm³); and, B) percentage patients by WHO clinical stage.</p

Flowchart highlighting enrolled patient population.

<p>Flowchart highlighting enrolled patient population.</p

Detection of EBOV antibodies, Lagos, Nigeria.

<p>(A) Sera samples from 3 EVD survivors, 10 documented EVD contacts, and 6 control HCWs were subjected to LFn-EBOV-GP1 and LFn-EBOV-sGP Western blot analysis. +, positive control. Molecular size marker units are kDa. EVD, Ebola virus disease. Control HCWs, control healthcare workers.</p